The Misidentified Variable

For decades, neurodivergence has been treated as pathology. We argue it has been misidentified — and that this misidentification has led to research methodologies, therapeutic interventions, and outcome measures that fail neurodivergent populations.

The Problem

Neurodivergence as Deficit

Clinical research has historically treated neurodivergent populations as "broken neurotypicals" — measuring outcomes against neurotypical baselines, adapting interventions designed for neurotypical brains, and defining success by proximity to neurotypical functioning.

This approach has produced catastrophic outcomes. Autistic adults face 9× higher suicide rates than the general population, 79% unemployment, and pervasive co-occurring mental health conditions. These are not inherent features of autism — they are the predictable results of a society and research establishment that has misidentified the variable.

The variable is not "how broken is this person?" The variable is "how different is this nervous system, and what does it need to thrive?"

Our Framework

Neurodivergence-by-Postulation

We propose a new research methodology: neurodivergence-by-postulation. This framework begins with the postulate that neurodivergent nervous systems are fundamentally different — not deficient — and that interventions must be designed from first principles rather than adapted from neurotypical protocols.

This means:

•Neurodivergent-centered study design — Autistic and neurodivergent individuals are involved in every phase of research, from hypothesis generation to interpretation of findings.
•Outcome measures that matter — We do not measure success by productivity, employment, or "normalization." We measure reduction in suffering, improvement in quality of life, and restoration of agency.
•First-principles intervention design — Therapeutic protocols are designed for neurodivergent neurology, accounting for sensory sensitivities, communication differences, and emotional regulation profiles.

This is not a minor methodological adjustment. It is a fundamental reorientation of how we approach neurodivergence in clinical research.

Research Domains

Multiple Therapeutic Pathways

The Cedar Institute funds research across three domains:

1. Psychedelic Medicine

We fund clinical trials of psychedelic compounds with pharmacological profiles suited to neurodivergent neurology — including 2C-B, psilocybin, and novel entactogens. Our first study investigates 2C-B-assisted therapy using the Karame Protocol.

2. Neuroplasticity Interventions

Not all therapeutic pathways require psychedelics. We support research into non-pharmacological interventions that leverage neuroplasticity, sensory integration, and trauma-informed protocols — including the Kairos Protocol and other modalities.

3. Community-Centered Research

All research we fund is neurodivergent-centered. We convene community advisory panels, implement trauma-informed consent protocols, and ensure that neurodivergent voices are not just consulted — they are authoritative.

Ethics

Our Commitments

We acknowledge the historical harm done to neurodivergent populations by medical and psychiatric institutions. We commit to:

•Transparency — All research funded by the Cedar Institute will be published in peer-reviewed journals and made publicly available.
•Accountability — We maintain strict conflict-of-interest policies and operate independently from any commercial enterprise.
•Nothing About Us Without Us — No research will be conducted on neurodivergent people — only with them.